Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AFLAC Incorporated (AFL) vs TransMedics Group Inc (TMDX) Price & Performance

AFLAC IncorporatedTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

AFLAC Incorporated vs TransMedics Group Inc — how do they compare? AFLAC Incorporated trades at $120.6 (market cap $60.70B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: AFLAC Incorporated is far larger — about 19.6× TransMedics Group Inc's market cap, and AFLAC Incorporated pays a 2.02% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

AFLTMDX
Market Cap
$60.70B$3.10B
Sector
FinancialsTechnology
52-Week High
$129.55$150.42
52-Week Low
$103.55$61.99
Enterprise Value
$70.65B$3.49B
Dividend Yield
2.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AFLAC Incorporated

AFL trades at $120.98, down 0.79% on the day, with a P/E of 13.06 and net income margin of 26.59%. Recent earnings missed estimates for three consecutive quarters, with Q3 2026 results pending. Technical indicators show a bullish overall signal despite bearish moving averages and oscillators. The company maintains a strong dividend history, with recent payouts of $0.61 per share.

Outlook remains mixed; solid profitability and dividend growth support income investors, but earnings misses and revenue declines pose near-term risks. Analyst consensus is cautious with a hold-heavy rating and price target of $118, slightly below current levels. Key catalysts include U.S. sales momentum and Japan unit performance, while currency headwinds and medical cost inflation are concerns.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.

Read more on AFL

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX